20 Jul

Biopharma M&A has fallen off a cliff – but IP owners in the sector have reasons to be cheerful

Acquisitions of life sciences companies have dropped off to an astonishing extent during the first half of this year, but biopharma innovators still have plenty of ways to monetise their IP

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth